DNA X amends 8-K to update disclosure on Series B preferred stock sale for $2.5 million
Reuters2026/08/13 20:02- DNA X filed an amended 8-K to update its disclosure under Item 3.02 on unregistered equity sales.
- It reported selling the remaining 416,667 shares of Series B Preferred Stock on Aug. 7 for cash proceeds of $2.5 million.
- Pro forma stockholders’ equity was estimated at $5.84 million as of Aug. 7, above Nasdaq’s $2.5 million continued-listing requirement.
- The company is awaiting Nasdaq’s formal determination that it has regained compliance with the stockholders’ equity rule.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
PetroTal forecasts FY2026 adjusted EBITDA at USD 110 million-120 million
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
